Our patients can schedule a COVID-19 vaccination through NYU Langone Health MyChart or the NYU Langone Health app. Learn more about the COVID-19 vaccine. Read our updated information about wearing a mask for your visit, and our visitor policy.
Clinical Trials and Research Studies
Phase 2
A Phase 2 randomized open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)
Learn MorePhase 5
A PHASE 1/2 OPEN-LABEL DOSE-ESCALATION SAFETY AND TOLERABILITY STUDY OF NC410 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Learn MorePhase 1
An Open-label Multicenter Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab a Human Bispecific EGFR and cMet Antibody for the Treatment of Subjects with Advanced Non-Small Cell Lung Cancer
Learn MorePhase 1
An Open Label Phase 1 Dose-Escalation Study to Evaluate the Safety and Preliminary Antitumor Activity of TAK-676 with Pembrolizumab Following Radiation Therapy in the Treatment of Non-Small-Cell Lung Cancer Triple-Negative Breast Cancer or Squamous Cell Carcinoma of the Head and Neck that has Progressed on Checkpoint Inhibitors
Learn More